TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27261989

Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation (KK) program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Music listening (ML) program
Number of subjects: 60
Study: 25076428

Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate (MA) treatment
Number of subjects: 57
Study: 22731734

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20407903

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRA using Gd-DOTA (intravenous bolus 0.1 mmol/kg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Unenhanced MRA
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRA using Gd-DOTA
Number of subjects: 92
Study: 18046999

Group type: EXPERIMENTAL
Intervention: 0.02% mitomycin C (MMC) applied topically for 2 minutes after PRK
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard PRK (no MMC)
Number of subjects: 28
Study: 16223398

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 150 microg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 1 microg/kg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Isotonic saline (Control group)
Number of subjects: 150
Study: 11887511

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Deionized distilled water (DDW)
Number of subjects: 40
Study: 9790199

Group type: EXPERIMENTAL
Intervention: Modified transection
Number of subjects: 83

Group type: COMPARATOR
Intervention: Classic transection
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study: 7630694

Group type: EXPERIMENTAL
Intervention: 84 J/oz formula
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 100.8 J/oz formula
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 52
Study: 2702793

Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 337078

Group type: EXPERIMENTAL
Intervention: Frubiase Calcium forte
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7030120

Group type: EXPERIMENTAL
Intervention: Disoprofol 1.2 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disoprofol 3 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexitone 1 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexitone 2 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disoprofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study: 31897405

Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28303758

Group type: EXPERIMENTAL
Intervention: 3 g n‐3 polyunsaturated fatty acids (PUFAs) per day
Number of subjects: 145

Group type: COMPARATOR
Intervention: 3 g olive oil per day (control)
Number of subjects: 145
Study: 27089418

Group type: EXPERIMENTAL
Intervention: Ginger extract (3g daily for 1 month)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (starch capsule)
Number of subjects: 69
Study: 22515652

Group type: EXPERIMENTAL
Intervention: Combination therapy using maxacalcitol lotion (weekdays) and betamethasone butyrate propionate lotion (weekends) for 4 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination therapy using maxacalcitol lotion (weekdays) and betamethasone butyrate propionate lotion (weekends) for 8 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Monotherapy with maxacalcitol lotion after combination therapy
Number of subjects: 37
Study: 23234560

Group type: EXPERIMENTAL
Intervention: Home-based arm ergometry aerobic exercise programme (moderate intensity 50-70% HRMax) for eight weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 20959428

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium for oral solution (50 mg)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study: 17503161

Group type: COMPARATOR
Intervention: Standard group (control)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Telephone group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Out-patient group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pooled telephone and outpatient group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Non-advised smokers
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Overall wound infection rate
Number of subjects: 180
Study: 15758600

Group type: EXPERIMENTAL
Intervention: Antithrombotic agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective thrombophilia screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acquired thrombophilia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heritable thrombophilias
Number of subjects: 0
Study: 12077953

Group type: EXPERIMENTAL
Intervention: Documentation of religious affiliation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Discussion of religious beliefs
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Staff training on religious awareness
Number of subjects: 23
Study: 10211496

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (enoxaparin)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 320
Study: 7886461

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment with a newly developed boot
Number of subjects: 50
Study: 2179477

Group type: EXPERIMENTAL
Intervention: CMFPT X 12 plus continuous tamoxifen
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: CMFPT X 12
Number of subjects: 803

Group type: COMPARATOR
Intervention: CMFPT X 4
Number of subjects: 803
Study: 26371

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled Isoprenaline (1,500 microgram)
Number of subjects: 12
Study: 29222947

Group type: EXPERIMENTAL
Intervention: Guselkumab (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Guselkumab (30 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Guselkumab (100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Guselkumab (300 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26972022

Group type: EXPERIMENTAL
Intervention: fcSEMS
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: uSEMS
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Plastic stents
Number of subjects: 54
Study: 25359128

Group type: EXPERIMENTAL
Intervention: FLOW dissemination (facilitator-led participatory approach)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional dissemination (one didactic session a year and distribution of educational material)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no dissemination)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All arms (FLOW, traditional, control)
Number of subjects: 30
Study: 23382472

Group type: COMPARATOR
Intervention: Trastuzumab plus docetaxel (HT); n = 70
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T‐DM1); n = 67
Number of subjects: 137
Study: 21409897

Group type: EXPERIMENTAL
Intervention: Single dose of prunes daily
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Double dose of prunes
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (plain water)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Test groups (prunes)
Number of subjects: 259
Study: 17905442

Group type: COMPARATOR
Intervention: Duloxetine alone (DLX)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Duloxetine plus telephone intervention (DLX+TI)
Number of subjects: 962
Study: 15938378

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (group I)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Standard enteral nutrition (group II)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Enteral nutrition enriched with glutamine, arginine, and omega-3 fatty acids (group III)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as comparison between groups)
Number of subjects: 62
Study: 12826854

Group type: EXPERIMENTAL
Intervention: Morphine with naloxone 0.8 mg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Morphine alone (placebo)
Number of subjects: 92
Study: 10921562

Group type: EXPERIMENTAL
Intervention: Dopamine (2.7±0.2 microg x kg(−1) x min(−1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dopexamine (0.7±0.1 microg x kg(−1) x min(−1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dobutamine (2.7±0.1 microg x kg(−1) x min(−1))
Number of subjects: 10
Study: 9120223

Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8263895

Group type: EXPERIMENTAL
Intervention: Mailed prescription-refill reminders
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Unit-of-use packaging
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Combination of mailed reminders and unit-of-use packaging
Number of subjects: 304

Group type: COMPARATOR
Intervention: Standard pharmaceutical care (Control)
Number of subjects: 304
Study: 2938986

Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment to control PRL levels during anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: No bromocriptine treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: General anesthesia and follicular aspiration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pregnancy after embryo transfer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Changes in PRL and P levels during oocyte retrieval
Number of subjects: 20
Study: 30095660

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.005 mg/kg, intramuscular injection)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no glycopyrrolate administration)
Number of subjects: 78
Study: 27895848

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 3428

Group type: EXPERIMENTAL
Intervention: amodiaquine-artesunate
Number of subjects: 3428

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 3428

Group type: EXPERIMENTAL
Intervention: mefloquine-artesunate
Number of subjects: 3428
Study: 24115149

Group type: EXPERIMENTAL
Intervention: MS group
Number of subjects: 26

Group type: COMPARATOR
Intervention: HC group
Number of subjects: 26
Study: 22048442

Group type: EXPERIMENTAL
Intervention: Continuous use of ASA
Number of subjects: 52

Group type: COMPARATOR
Intervention: Discontinuation of ASA
Number of subjects: 52
Study: 20720176

Group type: COMPARATOR
Intervention: EX‐FAST (noncaloric placebo)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EX‐FED (beverage containing 5 kcal, 0.83 g carbohydrate, 0.37 g protein, and 0.03 g fat)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EX‐FED
Number of subjects: 8

Group type: COMPARATOR
Intervention: EX‐FAST
Number of subjects: 8
Study: 18463425

Group type: EXPERIMENTAL
Intervention: Combined therapy with levocabastine hydrochloride ophthalmic suspension and pemirolast potassium ophthalmic solution
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single therapy with levocabastine hydrochloride ophthalmic suspension
Number of subjects: 32
Study: 16418140

Group type: EXPERIMENTAL
Intervention: Metoclopramide IV 0.5 mg 30 minutes before surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ondansetron IV 0.1 mg 30 minutes before surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (saline IV 30 minutes before surgery)
Number of subjects: 46
Study: 12908038

Group type: EXPERIMENTAL
Intervention: Pentamidine isothionate (4mg/kg/day on alternate days for one week)
Number of subjects: 79

Group type: COMPARATOR
Intervention: N-methylglucamine (20mgSbV/kg/day for 20 days)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pentamidine isothionate
Number of subjects: 79

Group type: COMPARATOR
Intervention: N-methylglucamine
Number of subjects: 79
Study: 10390744

Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg t.i.d. for one year
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 156
Study: 8695026

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study: 1716546

Group type: EXPERIMENTAL
Intervention: 400 mg hydrocortisone per day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 800 mg hydrocortisone per day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 6370437

Group type: EXPERIMENTAL
Intervention: Lorazepam (6 to 2 mg over 4 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chlordiazepoxide (150 to 50 mg over 4 days)
Number of subjects: 50
Study: 30653086

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg elemental selenium daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30158360

Group type: EXPERIMENTAL
Intervention: Having a person in need of nursing care at home
Number of subjects: 38958

Group type: COMPARATOR
Intervention: No person in need of nursing care at home
Number of subjects: 38958
Study: 26685791

Group type: EXPERIMENTAL
Intervention: 3% diquafosol 6 times a day
Number of subjects: 86

Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate 6 times a day
Number of subjects: 86
Study: 24639290

Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked spongostan
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no spongostan)
Number of subjects: 121
Study: 22677076

Group type: EXPERIMENTAL
Intervention: Combination of metformin (1000 mg twice daily) and pioglitazone (45 mg daily) for 3 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20673557

Group type: EXPERIMENTAL
Intervention: Atomoxetine and behavior therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Atomoxetine alone
Number of subjects: 56
Study: 17392557

Group type: EXPERIMENTAL
Intervention: Soy nut diet
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Soy protein diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control diet (DASH)
Number of subjects: 42
Study: 16344837

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended release (MAS XR) 20-60 mg/day
Number of subjects: 223
Study: 11897264

Group type: EXPERIMENTAL
Intervention: Synthesized pheromone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11122690

Group type: EXPERIMENTAL
Intervention: Lovastatin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline LDL-C levels as low as 125 mg/dL
Number of subjects: 0
Study: 7533484

Group type: COMPARATOR
Intervention: Intravenous hydromorphone via PCA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epidural hydromorphone via PCA
Number of subjects: 16
Study: 1732238

Group type: EXPERIMENTAL
Intervention: Partial meniscectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total meniscectomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Partial meniscectomy and Total meniscectomy
Number of subjects: 200
Study: 6372846

Group type: EXPERIMENTAL
Intervention: slow-release theophylline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ketotifen
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 29447357

Group type: EXPERIMENTAL
Intervention: Randomized releases of Wolbachia-infected Aedes aegypti mosquitoes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29533819

Group type: EXPERIMENTAL
Intervention: 10 Hz 2 mA peak-to-peak tACS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: 2 mA tDCS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: tACS, sham, and tDCS
Number of subjects: 22
Study: 26188918

Group type: EXPERIMENTAL
Intervention: Superior calyceal access (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inferior calyceal access (Group 2)
Number of subjects: 100
Study: 24091353

Group type: EXPERIMENTAL
Intervention: Cereal-based snack (high-sugar and high-glycemic index)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Raisin-based snack
Number of subjects: 79

Group type: COMPARATOR
Intervention: Peanut-butter-based snack
Number of subjects: 79
Study: 22168750

Group type: EXPERIMENTAL
Intervention: Silicone derivative plus onion extract gel (Cybele(®) scagel)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study: 20399336

Group type: EXPERIMENTAL
Intervention: Minor depression (2-4 symptoms)
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Major depression (5-6 symptoms)
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Major depression (7-9 symptoms)
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Comparison of minor and major depression
Number of subjects: 1129
Study: 18633050

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.2% at 8 mL/h with 3-mL bolus and 15-min lockout (15-min lockout group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.2% at 4 mL/h with 8-mL bolus and 30-min lockout (30-min lockout group)
Number of subjects: 37
Study: 16170975

Group type: EXPERIMENTAL
Intervention: Tooth wipe (Oral‐B Brush‐Ups)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 25
Study: 12238997

Group type: EXPERIMENTAL
Intervention: Prevention program focusing on education and supervision of coaches and players
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual training and playing without intervention
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Prevention program
Number of subjects: 194
Study: 9146440

Group type: EXPERIMENTAL
Intervention: Low-intensity dietary intervention (self-help booklet and brief motivational message)
Number of subjects: 2111
Study: 7959278

Group type: EXPERIMENTAL
Intervention: Tamoxifen (used for at least 1 year, median duration 4.5 years)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No Tamoxifen
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 73
Study: 3125307

Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone analogue (RX77368)
Number of subjects: 29
Study: 29383372

Group type: EXPERIMENTAL
Intervention: Counseling journal group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gratitude journal group
Number of subjects: 0
Study: 27028750

Group type: EXPERIMENTAL
Intervention: 3DP fast-melt formulation of levetiracetam
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional immediate-release tablet of levetiracetam (Keppra(®))
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 3DP fast-melt formulation of levetiracetam under fed conditions
Number of subjects: 33
Study: 24030782

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (normal 0.9% saline infusion)
Number of subjects: 64
Study: 22426346

Group type: EXPERIMENTAL
Intervention: Verteporfin PDT + Ranibizumab
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Verteporfin PDT
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 61
Study: 20132969

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19039458

Group type: EXPERIMENTAL
Intervention: Zyoptix LASIK
Number of subjects: 37

Group type: COMPARATOR
Intervention: Planoscan LASIK
Number of subjects: 37
Study: 16871592

Group type: EXPERIMENTAL
Intervention: MINO (Aerocrine)
Number of subjects: 55

Group type: COMPARATOR
Intervention: NIOX
Number of subjects: 55
Study: 14639068

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biocompatible membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow extended daily dialysis
Number of subjects: 0
Study: 11200149

Group type: EXPERIMENTAL
Intervention: Irinotecan/5-FU/leucovorin combinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard 5-FU/leucovorin regimens
Number of subjects: 0
Study: 8831922

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate given orally
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 1287614

Group type: EXPERIMENTAL
Intervention: Cefaclor AF 375 mg twice daily
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Cefaclor AF 500 mg twice daily
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Cefaclor AF 750 mg twice daily
Number of subjects: 1321

Group type: COMPARATOR
Intervention: Cefaclor 250 mg three times daily
Number of subjects: 1321

Group type: COMPARATOR
Intervention: Cefaclor 500 mg three times daily
Number of subjects: 1321
Study: 3891682

Group type: EXPERIMENTAL
Intervention: Proquazone 150 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Proquazone 75 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 31560093

Group type: EXPERIMENTAL
Intervention: Clinic-based adherence clubs
Number of subjects: 604

Group type: COMPARATOR
Intervention: Community-based adherence clubs
Number of subjects: 604
Study: 30044398

Group type: EXPERIMENTAL
Intervention: Investigational product containing extracts of white mulberry, white bean, and green coffee (with added fibre)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 25763849

Group type: EXPERIMENTAL
Intervention: Six-strand hamstring tendon (HT) allograft
Number of subjects: 129

Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) allograft
Number of subjects: 129
Study: 24433461

Group type: EXPERIMENTAL
Intervention: Village doctor-assisted case management (VD model)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Case as usual (CAU model)
Number of subjects: 400